NeurogesX Appoints New Board Director and Audit Committe...( SAN MATEO Calif. Au...)

SAN MATEO, Calif., Aug. 25 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the appointment of Bradford S. Goodwin to its Board of Directors as a director and Audit Committee chairman, effective August 20, 2009. Mr. Goodwin currently serves as President and CEO of Keren Pharmaceutical, a company focused on exploiting a novel, Nobel Prize winning method of gene silencing. He also serves as nonexecutive chairman of Facet Biotech Corp. and as a director of Rigel, Inc.

Following Mr. Goodwin's appointment, NeurogesX received a letter dated August 21, 2009 from the Listing Qualifications Staff of the Nasdaq. The letter indicated that the Company has regained compliance with Nasdaq's audit committee composition requirements for continued listing as set forth in Listing Rule 5605(c)(2)(A), which requires that the Company's Audit Committee be comprised of at least three members, each of whom are independent.

Mr. Goodwin is a healthcare industry veteran and has held executive positions and board seats at several biopharmaceutical companies. Prior to joining Keren Pharmaceutical, he served as Chief Executive Officer and director of Novacea, Inc. from 2001 to 2006. Previously, Mr. Goodwin was President, Chief Operating Officer and Co-founder of Collabra Pharma. Before starting Collabra, Mr. Goodwin held various senior executive positions over a 12-year tenure at Genentech, Inc., including Vice President of Finance, and was responsible for treasury, purchasing, risk management, real estate, controllership, tax and long-range planning.

In addition Mr. Goodwin has held nonexecutive chairman positions at CoTherix, Inc. and PDL BioPharma
'/>"/>